Overview

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
Phase:
Phase 1
Details
Lead Sponsor:
Sarfez Pharmaceuticals, Inc.
Treatments:
Furosemide
Torsemide